Your browser is no longer supported. Please, upgrade your browser.
Settings
AMRS [NASD]
Amyris, Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own0.50% Shs Outstand300.89M Perf Week-15.93%
Market Cap1.73B Forward P/E- EPS next Y-0.22 Insider Trans-8.55% Shs Float200.16M Perf Month-60.91%
Income-417.10M PEG- EPS next Q0.00 Inst Own41.90% Short Float15.50% Perf Quarter-58.76%
Sales356.80M P/S4.84 EPS this Y29.60% Inst Trans-8.55% Short Ratio6.25 Perf Half Y-64.29%
Book/sh-0.30 P/B- EPS next Y81.40% ROA-155.60% Target Price20.83 Perf Year116.73%
Cash/sh0.38 P/C15.04 EPS next 5Y30.00% ROE337.40% 52W Range2.56 - 23.42 Perf YTD-7.69%
Dividend- P/FCF38.48 EPS past 5Y40.80% ROI-269.30% 52W High-75.66% Beta1.44
Dividend %- Quick Ratio0.40 Sales past 5Y38.40% Gross Margin66.40% 52W Low122.66% ATR0.67
Employees595 Current Ratio0.60 Sales Q/Q39.70% Oper. Margin- RSI (14)20.54 Volatility8.13% 8.16%
OptionableYes Debt/Eq- EPS Q/Q70.20% Profit Margin- Rel Volume2.05 Prev Close5.96
ShortableYes LT Debt/Eq- EarningsNov 08 AMC Payout- Avg Volume4.97M Price5.70
Recom1.70 SMA20-29.93% SMA50-49.93% SMA200-60.35% Volume10,170,738 Change-4.36%
Oct-15-21Resumed Cowen Outperform $19
Jun-01-21Initiated HSBC Securities Buy $20
Mar-03-21Reiterated H.C. Wainwright Buy $11 → $35
Feb-26-21Initiated ROTH Capital Buy $20
Jan-06-21Upgrade Cowen Market Perform → Outperform $9
Nov-25-20Initiated Jefferies Buy $3.35
Nov-25-20Initiated Cowen Market Perform $5
Dec-12-19Initiated Oppenheimer Outperform $8
Nov-14-18Reiterated B. Riley FBR Buy $10 → $8
Jan-25-18Initiated B. Riley FBR, Inc. Buy $8
May-28-14Resumed Stifel Hold
Feb-10-12Downgrade Deutsche Bank Buy → Hold $20 → $9
Nov-02-11Downgrade Robert W. Baird Outperform → Neutral $25 → $16
Jan-28-11Downgrade Stifel Nicolaus Buy → Hold
Nov-08-10Initiated Stifel Nicolaus Buy $22
Nov-30-21 08:00AM  
Nov-23-21 04:05PM  
10:41AM  
Nov-18-21 09:12AM  
Nov-15-21 05:31PM  
Nov-11-21 07:15PM  
Nov-10-21 08:00AM  
Nov-09-21 02:50PM  
02:30AM  
Nov-08-21 06:05PM  
05:14PM  
04:35PM  
04:11PM  
10:15AM  
08:00AM  
Oct-28-21 03:06PM  
08:00AM  
Oct-27-21 06:17AM  
Oct-25-21 10:08AM  
Oct-20-21 06:17AM  
Oct-13-21 05:45AM  
Oct-12-21 05:43AM  
Oct-05-21 08:00AM  
Oct-01-21 08:00AM  
Sep-22-21 08:00AM  
Sep-13-21 06:51AM  
Sep-08-21 08:00AM  
Sep-07-21 08:00AM  
Aug-26-21 08:30AM  
Aug-24-21 08:30AM  
08:00AM  
Aug-23-21 08:00AM  
Aug-20-21 03:51PM  
10:12AM  
08:00AM  
Aug-19-21 08:00AM  
Aug-16-21 08:00AM  
04:15AM  
Aug-13-21 06:51PM  
05:09PM  
Aug-09-21 06:23AM  
Aug-05-21 07:30PM  
10:05AM  
08:00AM  
Aug-03-21 08:00AM  
06:16AM  
Jul-29-21 03:05PM  
Jul-22-21 08:00AM  
Jul-21-21 08:00AM  
Jul-16-21 10:38PM  
Jul-13-21 08:00AM  
Jul-11-21 08:43AM  
Jul-01-21 08:00AM  
Jun-17-21 08:00AM  
07:40AM  
Jun-16-21 08:03AM  
Jun-15-21 08:00AM  
Jun-02-21 08:00AM  
May-27-21 06:52AM  
May-18-21 08:00AM  
May-17-21 05:15PM  
May-11-21 03:56PM  
08:00AM  
May-07-21 01:01AM  
May-06-21 09:25AM  
08:00AM  
May-05-21 08:00AM  
07:07AM  
May-03-21 03:36PM  
03:23PM  
Apr-30-21 05:50PM  
Apr-29-21 05:06PM  
Apr-26-21 08:00AM  
Apr-21-21 08:00AM  
Apr-15-21 08:00AM  
Apr-14-21 08:00AM  
Apr-09-21 06:00AM  
Apr-07-21 05:45PM  
08:00AM  
Apr-05-21 04:05PM  
Apr-01-21 08:00AM  
Mar-31-21 08:00AM  
Mar-30-21 12:01PM  
Mar-29-21 04:58PM  
Mar-25-21 08:00AM  
Mar-16-21 08:00AM  
Mar-14-21 01:16PM  
Mar-12-21 10:50PM  
Mar-10-21 08:00AM  
Mar-09-21 08:00AM  
Mar-02-21 10:30PM  
08:47AM  
08:28AM  
07:36AM  
07:15AM  
Mar-01-21 10:12AM  
08:00AM  
Feb-26-21 10:50PM  
10:04AM  
Feb-25-21 08:00AM  
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOERR L JOHNDirectorSep 09Option Exercise2.873,778,23010,843,52073,935,024Sep 13 07:01 PM
ALVAREZ EDUARDOCHIEF OPERATING OFFICERSep 02Sale14.8617,605261,610371,335Sep 03 09:56 PM
KELSEY NICOLECHIEF LEGAL OFFICER- SECRETARYSep 02Sale14.863,48351,757155,772Sep 03 09:55 PM
Kieftenbeld HermanusCHIEF FINANCIAL OFFICERSep 02Sale14.8624,380362,287281,560Sep 03 09:54 PM
Hughes AnthonyCHIEF ACCOUNTING OFFICERSep 02Sale14.861,16217,26782,917Sep 03 09:54 PM
Melo JohnPresident and CEOJul 07Sale15.5395,1151,477,012548,277Jul 09 05:44 PM
Kung FrankDirectorApr 14Option Exercise4.761,212,7875,772,8666,796,205Apr 15 07:58 PM
Kung FrankDirectorApr 13Option Exercise4.261,943,6598,279,9878,463,618Apr 15 07:58 PM
Kung FrankDirectorApr 13Sale14.964,678,36370,000,006711,258Apr 15 07:58 PM
DOERR L JOHNDirectorDec 11Option Exercise2.875,000,00014,350,00070,156,794Dec 15 07:18 PM